Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The development of novel approaches that allow accurate targeting of therapeutics to the intestinal mucosa is a major task in the research on intestinal inflammation. For the first time, a live genetically modified bacterial strain has been approved by Dutch authorities as a therapeutic agent for experimental therapy of intestinal bowel disease (IBD) in humans. Genetically modified probiotics can very well be used as carriers for localized antigen delivery into the intestine. Therapeutic safety, however, of such a carrier organism, is crucial, especially when a specific probiotic strain has to be used under diseased conditions. In this study, we tested the potential of Escherichia coli NISSLE 1917 to serve as a safe carrier for targeted delivery of recombinant proteins to the intestinal mucosa. In a well-defined and very sensitive immunological system, we demonstrate that intestinal recombinant E. coli NISSLE 1917 has no effect on migration, clonal expansion and activation status of specific CD4+ T cells, neither in healthy mice nor in animals with acute colitis. Furthermore, recombinant E. coli NISSLE 1917 has no effect on the induction or breakdown of peripheral T-cell tolerance in an autoimmune environment. The excellent colonization properties of E. coli NISSLE 1917 render this strain an ideal candidate as carrier organism for gut-focused in situ synthesis of therapeutic molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Waidmann, M., Bechtold, O., Frick, J.-S., Lehr, H.-A., Schubert, S., Dobrindt, U., Loeffler, J., Bohn, E., & Autenrieth, I. B. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00672-3 · Cited by 234
Patzer, S. I., Baquero, M. R., Bravo, D., Moreno, F., & Hantke, K. (2003) · Microbiology · doi:10.1099/mic.0.26396-0 · Cited by 233
Cited by
The Human Intestinal Microbiome in Health and Disease
Lynch, S. V., & Pedersen, O. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1600266 · Cited by 3,637
Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity
Ukena, S. N., Singh, A., Dringenberg, U., Engelhardt, R., Seidler, U., Hansen, W., Bleich, A., Bruder, D., Franzke, A., Rogler, G., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001308 · Cited by 482
“characterized probiotics, and its therapeutic efficacy and safety have convincingly been proven [12–16].”
BackgroundSelf-citationHwang, I. Y., Koh, E., Wong, A., March, J. C., Bentley, W. E., Lee, Y. S., & Chang, M. W. (2017) · Nature Communications · doi:10.1038/ncomms15028 · Cited by 472
Zyrek, A. A., Cichon, C., Helms, S., Enders, C., Sonnenborn, U., & Schmidt, M. A. (2007) · Cellular Microbiology · doi:10.1111/j.1462-5822.2006.00836.x · Cited by 428
Self-citationClinical use of E. coli Nissle 1917 in inflammatory bowel disease
Schultz, M. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20377 · Cited by 310
Probiotics: Properties, Examples, and Specific Applications
Behnsen, J., Deriu, E., Sassone-Corsi, M., & Raffatellu, M. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a010074 · Cited by 293
Duan, F. F., Liu, J. H., & March, J. C. (2015) · Diabetes · doi:10.2337/db14-0635 · Cited by 263
The non-pathogenic Escherichia coli strain Nissle 1917 – features of a versatile probiotic
Sonnenborn, U., & Schulze, J. (2009) · Microbial Ecology in Health and Disease · doi:10.3109/08910600903444267 · Cited by 232
Expressing cytotoxic compounds in Escherichia coli Nissle 1917 for tumor-targeting therapy
Li, R., Helbig, L., Fu, J., Bian, X., Herrmann, J., Baumann, M., Stewart, A. F., Müller, R., Li, A., Zips, D., et al. (2019) · Research in Microbiology · doi:10.1016/j.resmic.2018.11.001 · Cited by 73
Effects of probiotics on the gastrointestinal tract
Snelling, A. M. (2005) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000182103.32504.e3 · Cited by 46
Somabhai, C. A., Raghuvanshi, R., & Nareshkumar, G. (2016) · PLOS ONE · doi:10.1371/journal.pone.0164860 · Cited by 36
Thorel, M., Mateos-Hernandez, L., Mulot, B., Azzouni, M. N., Hodžić, A., Gaillot, H., Ruel, Y., Desoubeaux, G., Delaye, J.-B., Obregon, D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.897223 · Cited by 11
“coli Nissle and stable and long-term antigen expression (92) render this strain an ideal candidate for an oral probiotic-based vaccine.”
Background
Metadata
- Authors
- Westendorf, A. M., Gunzer, F., Deppenmeier, S., Tapadar, D., Hunger, J. K., Schmidt, M. A., Buer, J., & Bruder, D.
- Venue
- FEMS Immunology & Medical Microbiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-03
- Volume
- 43
- Issue
- 3
- Pages
- 373-384
- ISSN
- 0928-8244 (ISSN-L)
- 1574-695X
- OpenAlex
- W1985381669
- Cited by
- 94
- References
- 2
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.